⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

MANKIND - Fundamental Analysis: Financial Health & Valuation

Back to List

Rating: 3.8

Last Updated Time : 25 May 26, 01:36 am

Fundamental Rating: 3.8

Stock Code MANKIND Market Cap 1,02,326 Cr. Current Price 2,479 ₹ High / Low 2,727 ₹
Stock P/E 48.2 Book Value 397 ₹ Dividend Yield 0.04 % ROCE 13.6 %
ROE 13.7 % Face Value 1.00 ₹ DMA 50 2,280 ₹ DMA 200 2,271 ₹
Chg in FII Hold -1.10 % Chg in DII Hold 1.20 % PAT Qtr 732 Cr. PAT Prev Qtr 512 Cr.
RSI 62.3 MACD 92.0 Volume 7,09,897 Avg Vol 1Wk 16,11,364
Low price 1,910 ₹ High price 2,727 ₹ PEG Ratio 2.38 Debt to equity 0.34
52w Index 69.7 % Qtr Profit Var 207 % EPS 49.4 ₹ Industry PE 30.5

📊 Core Financials: Mankind Pharma reported quarterly PAT of ₹732 Cr (up from ₹512 Cr), showing strong profitability growth. ROE at 13.7% and ROCE at 13.6% reflect moderate efficiency. Debt-to-equity ratio of 0.34 indicates manageable leverage. EPS at ₹49.4 is decent, supported by consistent earnings momentum.

💹 Valuation Indicators: Stock P/E of 48.2 is significantly higher than the industry average (30.5), suggesting overvaluation. Book value at ₹397 vs CMP ₹2,479 shows a steep premium. PEG ratio of 2.38 indicates earnings growth is slower relative to valuation. Intrinsic value appears lower than CMP, limiting near-term upside.

💊 Business Model & Advantage: Mankind Pharma operates in pharmaceuticals with a strong presence in generics, branded formulations, and consumer healthcare. Competitive advantage lies in brand recognition, wide distribution, and diversified portfolio. However, high valuations and moderate efficiency metrics reduce attractiveness.

📈 Entry Zone & Holding Guidance: The stock trades above DMA 50 (₹2,280) and DMA 200 (₹2,271), showing strong momentum. RSI at 62.3 indicates mildly overbought conditions. A better entry zone would be closer to ₹2,300–₹2,400. Long-term holding is viable given industry demand, but fresh entry at current levels is risky due to stretched valuations.

Positive

  • ✅ Strong quarterly PAT growth (₹512 Cr → ₹732 Cr)

  • ✅ EPS at ₹49.4, reflecting solid earnings base

  • ✅ Diversified portfolio across pharma and consumer healthcare

  • ✅ DII holding increased by 1.20%, showing domestic institutional confidence

Limitation

  • ⚠️ High P/E (48.2) vs industry average (30.5)

  • ⚠️ PEG ratio of 2.38, showing slower earnings growth relative to valuation

  • ⚠️ Dividend yield at 0.04%, limited income support

Company Negative News

  • 📉 FII holding decreased by 1.10%, showing reduced foreign investor confidence

Company Positive News

  • 📈 Quarterly profit growth of 207% indicates strong operational momentum

  • 📈 Strong brand presence and diversified product portfolio support long-term growth

Industry

  • 🌐 Pharma industry PE at 30.5, reflecting moderate valuations

  • 🌐 Long-term demand supported by generics, branded formulations, and healthcare expansion

Conclusion

🔎 Mankind Pharma shows strong profitability growth and brand strength but trades at stretched valuations compared to peers. Entry near ₹2,300–₹2,400 offers better risk-reward. Long-term investors may hold cautiously, supported by industry demand and diversified portfolio, but valuation risks must be monitored.

For deeper insights, you could explore a peer comparison or a valuation analysis to assess its position against competitors and intrinsic value.

Back to List
Technical Analysis
Fundamental Analysis

NIFTY 50 - Fundamental Stock Watchlist

NEXT 50 - Fundamental Stock Watchlist

MIDCAP - Fundamental Stock Watchlist

SMALLCAP - Fundamental Stock Watchlist